Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| pericyte | 18 studies | 39% ± 12% | |
| ciliated cell | 17 studies | 48% ± 16% | |
| smooth muscle cell | 16 studies | 31% ± 13% | |
| fibroblast | 5 studies | 21% ± 4% | |
| myofibroblast cell | 5 studies | 23% ± 4% | |
| cardiac muscle cell | 5 studies | 35% ± 9% | |
| deuterosomal cell | 4 studies | 18% ± 3% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| kidney | 84% | 2781.43 | 75 / 89 | 93% | 128.53 | 842 / 901 |
| lung | 97% | 3589.38 | 561 / 578 | 67% | 37.37 | 770 / 1155 |
| esophagus | 97% | 3653.73 | 1398 / 1445 | 58% | 35.57 | 107 / 183 |
| uterus | 87% | 1616.94 | 148 / 170 | 63% | 72.42 | 290 / 459 |
| bladder | 86% | 1914.52 | 18 / 21 | 40% | 36.88 | 204 / 504 |
| thymus | 59% | 818.38 | 386 / 653 | 58% | 30.17 | 351 / 605 |
| ovary | 71% | 1084.89 | 128 / 180 | 39% | 15.50 | 169 / 430 |
| prostate | 52% | 1084.49 | 127 / 245 | 49% | 13.27 | 247 / 502 |
| muscle | 100% | 30414.99 | 803 / 803 | 0% | 0 | 0 / 0 |
| heart | 98% | 13269.37 | 843 / 861 | 0% | 0 | 0 / 0 |
| blood vessel | 96% | 5416.65 | 1282 / 1335 | 0% | 0 | 0 / 0 |
| breast | 76% | 1616.93 | 349 / 459 | 12% | 3.20 | 132 / 1118 |
| adrenal gland | 53% | 958.64 | 137 / 258 | 31% | 29.35 | 71 / 230 |
| adipose | 78% | 2695.05 | 939 / 1204 | 0% | 0 | 0 / 0 |
| intestine | 51% | 756.65 | 489 / 966 | 27% | 9.48 | 144 / 527 |
| tonsil | 0% | 0 | 0 / 0 | 76% | 61.01 | 34 / 45 |
| pancreas | 0% | 0 | 0 / 328 | 71% | 28.57 | 127 / 178 |
| stomach | 33% | 655.19 | 118 / 359 | 28% | 8.41 | 81 / 286 |
| skin | 35% | 585.02 | 628 / 1809 | 5% | 4.12 | 25 / 472 |
| brain | 8% | 155.72 | 204 / 2642 | 25% | 5.07 | 176 / 705 |
| liver | 4% | 71.19 | 10 / 226 | 20% | 5.59 | 81 / 406 |
| lymph node | 0% | 0 | 0 / 0 | 21% | 7.46 | 6 / 29 |
| peripheral blood | 2% | 31.97 | 18 / 929 | 0% | 0 | 0 / 0 |
| spleen | 2% | 33.83 | 4 / 241 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0007264 | Biological process | small GTPase-mediated signal transduction |
| GO_0005829 | Cellular component | cytosol |
| GO_0005886 | Cellular component | plasma membrane |
| GO_0005246 | Molecular function | calcium channel regulator activity |
| GO_0005525 | Molecular function | GTP binding |
| GO_0005516 | Molecular function | calmodulin binding |
| GO_0005515 | Molecular function | protein binding |
| GO_0003924 | Molecular function | GTPase activity |
| Gene name | RRAD |
| Protein name | GTP-binding protein RAD (RAD1) (Ras associated with diabetes) RRAD, Ras related glycolysis inhibitor and calcium channel regulator |
| Synonyms | RAD |
| Description | FUNCTION: May regulate basal voltage-dependent L-type Ca(2+) currents and be required for beta-adrenergic augmentation of Ca(2+) influx in cardiomyocytes, thereby regulating increases in heart rate and contractile force (By similarity). May play an important role in cardiac antiarrhythmia via the strong suppression of voltage-gated L-type Ca(2+) currents (By similarity). Regulates voltage-dependent L-type calcium channel subunit alpha-1C trafficking to the cell membrane (By similarity). Inhibits cardiac hypertrophy through the calmodulin-dependent kinase II (CaMKII) pathway . Inhibits phosphorylation and activation of CAMK2D . . |
| Accessions | ENST00000299759.11 P55042 J3KRG9 ENST00000568915.5 ENST00000566577.1 J3KSM6 |
